Navigation Links
EnVivo Initiates Phase IIb Alzheimer's Disease Trial For EVP-6124
Date:5/11/2010

WATERTOWN, Mass., May 11 /PRNewswire/ -- EnVivo Pharmaceuticals today announced the initiation and dosing of patients in a Phase IIb study of its EVP-6124 compound, a selective alpha-7 nicotinic agonist in patients with mild to moderate Alzheimer's disease.  The multi-center, dose ranging, placebo controlled, six-month study taking place in the U.S. and Europe is designed to determine the safety and efficacy of EVP-6124 in producing procognitive effects and improving the clinical condition of Alzheimer's disease patients.

"Patients with Alzheimer's disease have a number of symptomatic therapies available to them. However, the effects of the available medications are modest. Even if significant progress is made in slowing disease progression, more effective therapies that sustainably improve the cognition of the patients are clearly needed," said Kees Been, EnVivo president and CEO. "There is growing consensus that alpha-7 nicotinic agonists can potentially improve the cognitive function in Alzheimer's disease patients as evidenced by the number of large pharmaceutical companies advancing similar drugs through development. The potential upside for patients is considerable and we look forward to completing our Alzheimer's disease study by the middle of next year."

The Phase IIb study will enroll mild to moderate Alzheimer's disease patients who will be randomized to three separate doses of EVP-6124 or placebo over six months. Efficacy will primarily be determined by the ADAS-Cog scale, a commonly used and accepted measure of cognition in patients with Alzheimer's disease. Secondary assessments will include other cognitive and clinical measures. EVP-6124 also is being tested in patients with schizophrenia in a separate Phase IIb study that started in late 2009
'/>"/>

SOURCE EnVivo Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. EnVivo Pharmaceuticals Names Stephen DiPalma Chief Financial Officer
2. EnVivo Pharmaceuticals Announces Results and Successful Completion of EVP-6124 Phase Ib/IIa Trial at the International Conference on Alzheimers Disease
3. EnVivo Pharmaceuticals Announces Reversal of Cognitive Deficits in Alzheimers Disease Transgenic Mouse Model With Gamma-Secretase Modulator
4. EnVivo Pharmaceuticals Announces Executive Appointment
5. Harbinger Research Initiates Coverage on China Baicaotang Medicine, Ltd.
6. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1/2 Combination Study of MM-121 and Tarceva in Patients with Non-Small Cell Lung Cancer
7. Aegera Therapeutics Initiates a Randomized Phase 2 Study with AEG35156 for the Treatment of Hepatocellular Carcinoma
8. AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma
9. Eppendorf Successfully Initiates Import ban Against Nanosphere, Inc. for the Countries of the European Union
10. Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia
11. Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... October 31, 2014 Jeffrey T. Manuel, ... Historical Studies within the College of Arts and Sciences, ... record the history of alcohol-based fuels in Illinois. ... others have been working to build Illinois’ biofuels industry ... overlooked aspect of the state's agricultural and business history. ...
(Date:10/31/2014)... 2014 ENVIRON , an ... today that Dr. Harvey Clewell III has rejoined ... work closely with senior professionals in ENVIRON’s Health ... serve at The Hamner Institutes for Health Sciences ... where he is Director, Center for Human Health ...
(Date:10/30/2014)... 2014 Investor-Edge has initiated coverage ... ONVO), Medivation Inc. (NASDAQ: MDVN ), Pharmacyclics ... (NYSE MKT: SYN), and Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD). ... at: http://investor-edge.com/register . On Wednesday, October ... 0.33%, the Dow Jones Industrial Average declined 0.18%, to ...
(Date:10/30/2014)... 30, 2014 SoundConnect , ... offers Office 365 end users the key to ... phone system by adding voice enablement and hybrid ... Lync Online, a communication tool that includes presence, ... hosted voice, O365 becomes a comprehensive unified communications ...
Breaking Biology Technology:SIUE History Prof Manuel Working on Biofuels Book with NCERC 2SIUE History Prof Manuel Working on Biofuels Book with NCERC 3Internationally recognized health scientist Dr. Harvey Clewell renews association with ENVIRON 2Internationally recognized health scientist Dr. Harvey Clewell renews association with ENVIRON 3Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 2Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 3Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 4Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 5SoundConnect Launches Voice Enablement and Hybrid Audio Conferencing for Office 365 2SoundConnect Launches Voice Enablement and Hybrid Audio Conferencing for Office 365 3
... Calif., Feb. 4 Arryx, Inc.,announced the addition ... Holographic Optical Trapping ("HOT") product line. The HOTkit,Complete ... events, and now, through the power of light, ... The HOTkit Complete was unveiled February 4 ...
... HORSHAM, Pa., Feb. 4 Centocor, Inc. announced ... (CNTO 1275),has been accepted for review by the ... of adult patients with chronic moderate to severe ... with a novel,mechanism of action that targets the ...
... HAVEN, Conn., Feb. 4 VION,PHARMACEUTICALS, INC. (Nasdaq: ... the Company,s senior management team as Vice President,Medical., ... pleased,to have Bill Hahne joining Vion in medical affairs. ... will be extremely useful to our,efforts to file a ...
Cached Biology Technology:Arryx Launches HOTkit(TM) Complete for Dynamic, Scientific Manipulation of Microscopic Elements 2Arryx Launches HOTkit(TM) Complete for Dynamic, Scientific Manipulation of Microscopic Elements 3Centocor Announces Ustekinumab Biologic License Application Accepted for Filing by FDA 2Centocor Announces Ustekinumab Biologic License Application Accepted for Filing by FDA 3Vion Pharmaceuticals Adds William Hahne, M.D. to Senior Management Team 2Vion Pharmaceuticals Adds William Hahne, M.D. to Senior Management Team 3
(Date:10/29/2014)... open for the Society of Interventional Radiology,s ... is the one place where interventional radiologists, ... care professionals can come together to find ... being presented, discussed and tested. , ... image-guided medicine, SIR 2015 will feature essential ...
(Date:10/29/2014)... and industrial products are in the environment – and ... them, scientists have yet to determine whether they cause ... doing that by estimating which substances people are exposed ... the ACS journal Environmental Science & Technology . ... risks to human health of any given substance depend ...
(Date:10/29/2014)... LANSING, Mich. – As bodies decompose, their types ... the clues they provide could mean the difference ... , Michigan State University is using a more ... help Detroit death-scene investigators examine these changing populations. ... as geographical location of death, gender, race, socioeconomic ...
Breaking Biology News(10 mins):SIR 2015: Interventional radiology shapes tomorrow's medicine 2MSU partners with Detroit to investigate death scenes 2
... of California, San Diego has discovered a molecule in ... or Bt toxin--a pesticide produced by bacteria and widely ... to ward off insect pests. , Their findings should ... prevent insects, which the researchers believe also possess the ...
... scientific world has accepted for more than 100 ... by their grandparents, bypassing genetic abnormalities carried by ... have hidden templates containing genetic information from the ... offspring, even though the traits aren't evident in ...
... to coax mouse stem cells to transform themselves into fat ... naturally do in the body. , While other studies have ... cells never completely functioned in the same way they do ... biologic components that all cells require to do their work. ...
Cached Biology News:UCSD discovery may help extend life of natural pesticide 2UCSD discovery may help extend life of natural pesticide 3Plants defy Mendel's inheritance laws, may prompt textbook changes 2Plants defy Mendel's inheritance laws, may prompt textbook changes 3Tiny scaffolding allows stem cells to become working fat cells 2Tiny scaffolding allows stem cells to become working fat cells 3
...
Tan solid. A glycoside used to permeabilize cellular membranes. Exhibits hemolytic activity. Contaminants: ash: ≤10%. Soluble in H 2 O. pH 4.4 - 4.6. RTECS VQ1400000, CAS 8047-15-2. References:...
...
... utilizes a silica based spin filter membrane to ... desired DNA band is cut from an agarose ... unit. The gel slice is melted irreversibly in ... is bound to the silica spin filter membrane ...
Biology Products: